877 / 1816
EORTC trial 22922/10925
1996-2004
Eligible: pN0 with centrally/medially tumour or pN+
R to +/- RT to IM-MS, mostly including IC3
Primary endpoint: OS
Secondary endpoints: DFS and BCM
4004 patients, 44% node-negative
Around 25% had mastectomy
Median follow up 10.9 yr